Parkinson's disease fingerprint study with LRRK2 gene focus
Part of Brain & nervous system clinical trials.
This study looks at a specific genetic change (LRRK2) that may be linked to Parkinson's disease. It uses advanced genetic testing and MRI scans to learn more about how this condition develops and progresses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 30 and 80 years old
- You have been diagnosed with Parkinson's disease by a movement disorder specialist using standard criteria
- Your Parkinson's disease is at an early to moderate stage (Hoehn and Yahr stage 1 to 3)
- You are one of 10 people with a known LRRK2 gene change or 10 people with no known genetic cause
- You can consent to participate
- You do not have other neurological conditions, recent infections, active cancer, or autoimmune diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses blood tests and brain imaging to understand how Parkinson's disease spreads. It may help find early signs and new treatment targets.
This research study uses advanced MRI brain imaging to understand how a specific gene mutation (LRRK2) affects certain brain chemicals in people with Parkinson's disease. The goal is to learn more about how this genetic form of Parkinson's works, which could help develop better treatments.
This study is a registry that collects information from people with Parkinson’s who have specific LRRK2 gene changes. It helps researchers understand how this genetic form of Parkinson’s behaves over time.
This study builds a genetics “registry” of people diagnosed with Parkinson’s disease who agree to genetic testing. Your information may help researchers understand why Parkinson’s happens and improve future treatments.
This trial tests an experimental drug called NEU-411 for people with early Parkinson's disease who have a specific genetic change (LRRK2). It aims to see if the drug can slow the disease progression.
This study uses advanced genetic testing (genome and RNA sequencing) to find the genetic causes of Parkinsonism that starts before age 40 or runs in families. If you join, you will provide a blood sample and a small skin biopsy to help researchers understand your condition better.
Hear when a new Parkinsons Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.